Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This phase III trial studies combination chemotherapy and atezolizumab to see how well it
works compared with combination chemotherapy alone in treating patients with stage III colon
cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination
chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving combination chemotherapy with
atezolizumab may work better than combination chemotherapy alone in treating patients with
colon cancer.
This phase III trial studies how well vitamin D3 given with standard chemotherapy and
bevacizumab works in treating patients with colorectal cancer that has spread to other parts
of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and
teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and
irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vitamin
D3 with chemotherapy and bevacizumab may work better in shrinking or stabilizing colorectal
cancer. It is not yet known whether giving high-dose vitamin D3 in addition to chemotherapy
and bevacizumab would extend patients' time without disease compared to the usual approach
(chemotherapy and bevacizumab).
This randomized phase II clinical trial studies how well nivolumab after combined modality
therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy
with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread.
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in
addition to standard of care chemotherapy and radiation therapy in patients with esophageal
and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with
antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's immune
system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and
radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be
removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and
radiation therapy might be more effective in patients with esophageal and gastroesophageal
junction adenocarcinoma who are undergoing surgery.
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and
capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with
radiation therapy may kill more tumor cells. This study may help doctors find out if
lower-dose chemoradiation is as effective and has fewer side effects than standard-dose
chemoradiation, which is the usual approach for treatment of this cancer type.
This randomized phase II trial studies how well veliparib or pembrolizumab work with
combination chemotherapy and radiation therapy in treating patients with rectal cancer that
has spread from where it started to nearby tissue or lymph nodes (locally advanced).
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor
cells to grow and spread. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Radiation therapy uses
high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib or pembrolizumab
with combination chemotherapy and radiation therapy may kill more tumor cells, make the tumor
smaller, and reduce the amount of normal tissue that needs to be removed.
This randomized phase III trial studies how well combination chemotherapy, bevacizumab,
and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as bevacizumab and atezolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving combination
chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with
colorectal cancer.
This randomized phase III trial studies how well combination chemotherapy, bevacizumab,
and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as bevacizumab and atezolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving combination
chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with
colorectal cancer.
The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
This randomized phase II trial studies how well cabozantinib s-malate, crizotinib,
savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread
from where it started to nearby tissue or lymph nodes or to other places in the body.
Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating
patients with kidney cancer compared to sunitinib malate.
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to
cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified
colorectal cancer that has spread from where it started to other places in the body and
cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and
irinotecan hydrochloride in treating patients with colorectal cancer.
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or
without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers
that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine
hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or
without nab-paclitaxel may work better at treating biliary tract cancers.
This study will examine the association between low muscle mass (myopenia) at diagnosis and
chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management